Wednesday, July 8, 2026

pharma · Breast Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · ALXO

ALX ONCOLOGY HOLDINGS

ALX ONCOLOGY HOLDINGS clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US HQ
2015 Founded
2 Employees
Public company Type
ALXO · NYSE Ticker
Company details
Status
Public
HQ
4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US
Founded
2015
Employees
2
Programs
13
Drugs
16
Patents
0
Intelligence · Clinical Programs

ALX ONCOLOGY HOLDINGS projects

13 ClinicalTrials.gov programs sponsored by ALX ONCOLOGY HOLDINGS.

ALX ONCOLOGY HOLDINGS has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Gastric Cancer

    phase 3 small molecule active

    1 trial
  2. AT148009

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer

    phase 2 small molecule active

    1 trial
  3. AZACITIDINE

    ALX ONCOLOGY HOLDINGS INC

    Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease

    phase 2 small molecule active

    1 trial
  4. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Microsatellite Stable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial
  5. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer, Metastatic

    phase 2 small molecule active

    1 trial
  6. Pembrolizumab

    ALX ONCOLOGY HOLDINGS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial
  7. Zanidatamab

    ALX ONCOLOGY HOLDINGS INC

    HER2-expressing Cancers

    phase 2 small molecule completed

    1 trial
  8. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Head and Neck Cancer

    phase 2 small molecule active

    2 trials
  9. ALX2004

    ALX ONCOLOGY HOLDINGS INC

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial
  10. Evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Bladder Cancer

    phase 1 small molecule completed

    1 trial
  11. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial
  12. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Higher Risk Myelodysplastic Syndromes

    phase 1 small molecule terminated

    1 trial
  13. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does ALX ONCOLOGY HOLDINGS have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.